This study aims to evaluate the psychometric properties of the Turkish version of the Parent-reported Drug Hypersensitivity Quality of Life Questionnaire (P-DrHy-Q), a disease-specific instrument assessing the health-related quality of life (HRQoL) in caregivers of children with suspected or confirmed drug hypersensitivity reactions. The P-DrHy-Q is designed to capture the psychosocial burden experienced by caregivers and includes two main domains: Mental Health and Social Activity. This study involves a forward-backward translation process, cultural adaptation, internal consistency analysis, and test-retest reliability assessment in a Turkish caregiver population.

Inclusion Criteria:

• Age ≥ 18 years
• Primary caregiver of a child under the age of 18
• Child must have a documented history of drug hypersensitivity
• Fluent in written and spoken Turkish
• Willingness to participate and provide written informed consent
• Availability to complete both baseline and follow-up questionnaire within the designated time frame

Exclusion Criteria:

• Caregivers with diagnosed psychiatric or cognitive disorders
• Inability to read or write in Turkish
• Child currently experiencing an acute drug hypersensitivity reaction
• Previous participation in the pilot testing phase of this validation study

The study population will consist of adult caregivers (parents or legal guardians) of children under the age of 18 who have a medically confirmed history of drug hypersensitivity. Participants will be recruited from a tertiary care pediatric allergy outpatient clinic. All participants must be fluent in Turkish and able to provide informed consent. The population represents a real-world sample of caregivers managing children with various types of drug allergies, including but not limited to reactions to antibiotics, antipyretics, and nonsteroidal anti-inflammatory drugs (NSAIDs). A subgroup of caregivers will be invited to complete the questionnaire twice to assess test-retest reliability.

This study does not plan to share individual participant data (IPD) due to the sensitive nature of patient and caregiver health information. All data will be analyzed and reported in aggregate form to protect participant confidentiality. Only authorized members of the research team will have access to the raw data, which will be stored securely in accordance with institutional and ethical guidelines.